Relmada Therapeutics' Chief Scientific Officer Dr. Richard Mangano to Speak about d-Methadone as a Potential Rapid Acting Antidepressant at Neuro Advance Boston
Panel Discussion on October 5, 2016 Begins at 4:20 p.m. Eastern Time.
NEW YORK, Sept. 28, 2016 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Dr. Richard Mangano, the company's chief scientific officer, will participate in a panel of thought leaders regarding N-methyl-D-aspartate (NMDA) receptor antagonists as a new therapeutic option to treat depression. The panel discussion will be held at the Neuro Advance Boston Conference on October 5, 2016, held at Harvard Medical School.
"Expanding interest in the use of ketamine and other NMDA receptor antagonists is a reflection of the limited range of safe and efficacious options available to treat depression," noted Dr. Mangano. "Our rapidly expanding understanding of the neurobiology of depression and mechanism of action of the NMDA receptor and its signal transduction pathway provides several potential new targets for treatment of depression that may overcome the limitations of current therapy. Relmada is working to advance research evaluating NMDA antagonist activity associated with d-Methadone as a potential rapid acting treatment for depression."
About Neuro Advance Boston
Neuro Advance Boston brings together leading neuro experts from industry and academia along with key members of the healthcare investment community to brainstorm about the most pressing issues facing neuro drug development. Interactive panels feature CEOs, CMOs, CSOs, and Heads of Neuro from top biopharmaceutical companies in the neuro space, along with leading academics and healthcare investors discussing everything from gene therapy to advances in psychiatry to novel therapeutic approaches.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.
Michael Becker, Chief Financial Officer
Relmada Therapeutics Inc.
Berry & Company Public Relations
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-chief-scientific-officer-dr-richard-mangano-to-speak-about-d-methadone-as-a-potential-rapid-acting-antidepressant-at-neuro-advance-boston-300335354.html
SOURCE Relmada Therapeutics, Inc.
Released September 28, 2016